[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583936":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":11,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":11,"overallStatus":42,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"135 patients are infused with 1×10⁸ stem cells per session","EXPERIMENTAL",null,[13,14],"Biological: CD83-positive MSC","Biological: regulatory MSC",{"label":16,"type":17,"description":11,"interventionNames":18},"45 patients are infused with equal volume of control solution","SHAM_COMPARATOR",[19],"Other: control solution",[21,26,30],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":11},"BIOLOGICAL","CD83-positive MSC","90 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":11},"regulatory MSC","45 patients are infused with 1×10⁸ stem cells per session and receive regulatory treatment",[9],{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"control solution","45 patients are infused with equal volume of control solution and receive regulatory treatment",[16],[35],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"Xiang Xu, Professor","CONTACT","+8613637843870","xiangxu@tmmu.edu.cn",[41],{"facility":5,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Chongqing","Chongqing Municipality","400010","China","CN",{"type":49,"coordinates":50},"Point",[51,52],106.55771,29.56026,{"lat":52,"lon":51},[55],{"name":56,"role":37,"phone":38,"phoneExt":11,"email":39},"Xiang Xu, Doctor of Medicine",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","xu xiang","Professor","100583936","early-phase-1-human-umbilical-cord-mesenchymal-stem-cells-treatment-in-sepsis-100583936",false,"NCT06882811","Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis","Clinical Study on Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Sepsis","Inclusion Criteria:\n\n* Age: 0-65 years old, diagnosed with sepsis\n* Clinical diagnosis of sepsis (based on Sepsis 3.0 International Guidelines)\n* Confirmed or suspected infection\n\nExclusion Criteria:\n\n* Violation of medical ethics\n* Significant confounding factors likely to bias study outcomes\n* Poor adherence to the study protocol\n* Concurrent participation in other clinical trials\n* Specific medical conditions:\n\n  1. History of chronic enteritis, neuropsychiatric disorders, or transplantation (bone marrow, lung, liver, pancreas, or small intestine)\n  2. Severe primary diseases affecting survival (e.g., life-limiting hepatic, renal, or endocrine disorders) or psychiatric disorders\n  3. History of hypersensitivity or severe adverse reactions to biological products\n  4. Imminent terminal status (e.g., septic shock, life expectancy \\\u003C7 days)\n  5. Foreseeable risk of medical errors or disputes during hospitalization\n  6. Active drug-resistant infections\n  7. History of malignancy at screening\n  8. Pregnancy, lactation, or plans for pregnancy within the next year","ALL","0 Years","65 Years",{"count":72,"type":73},180,"ESTIMATED","INTERVENTIONAL",[76],"EARLY_PHASE1","The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide theoretical basis and clinical research data for establishing a safe, effective and feasible clinical treatment plan for sepsis using stem cells.",[79],"Sepsis","2025-05-23",{"date":82,"type":83},"2025-05-25","ACTUAL",{"date":85,"type":83},"2025-05-22",{"date":87,"type":73},"2027-12-31",{"name":5,"class":6},1]